NCT05432544

Safety and Tolerability of SHR-1918 in Healthy Subjects

A Phase 1, Randomized, Double Blind, Dose-escalation, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Injection of SHR-1918 Injection in Healthy Subjects

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 72 (actual)
• Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The primary objective of this study is to assess the safety and tolerability of SHR-1918 injection in healthy subjects. In addition, this study will provide information on pharmacokinetics and pharmacodynamics of SHR-1918 injection in healthy subjects.

Conditions

• Hyperlipemia

Interventions

Type	Name	Description
DRUG	SHR-1918	Ascending dose
DRUG	SHR-1918 placebo	Ascending dose

Timeline

• Start date: 2022-06-27
• Primary completion: 2023-12-11
• Completion: 2023-12-12
• First posted: 2022-06-27
• Last updated: 2023-07-06

Locations

1 site across 1 country: China